Search

The First-Ever Drug to Treat Peanut Allergies Is Coming

THE FIRST-EVER DRUG TO TREAT PEANUT ALLERGIES IS COMING

The world's first peanut-allergy drug is officially on its way. Aimmune Therapeutics, a major US biotech company, just wrapped up a...

 
 
 
Aimmune's Peanut Allergy Drug Hits Study Goals, FDA Filing Planned

AIMMUNE'S PEANUT ALLERGY DRUG HITS STUDY GOALS, FDA FILING PLANNED

Peanuts rank among the top foods that spark allergic reactions, prompting schools to ban peanut butter sandwiches and travelers to...

INVESTIGATING THE THERAPEUTIC POTENTIAL AND MECHANISM OF CURCUMIN IN BREAST CANCER BASED ON RNA SEQUENCING AND BIOINFORMATICS ANALYSIS

Abstract Background Breast cancer is a prevalent cancer in female. This study aims to investigate the therapeutic potential and mechanism...

 
 
 
Bio Roundup: Trump's Budget, Biogen's AD Reveal, Hugin's Run & More

BIO ROUNDUP: TRUMP'S BUDGET, BIOGEN'S AD REVEAL, HUGIN'S RUN & MORE

Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration's 2019 budget...

Bio Roundup: Trump's Budget, Biogen's AD Reveal, Hugin's Run & More

BIO ROUNDUP: TRUMP'S BUDGET, BIOGEN'S AD REVEAL, HUGIN'S RUN & MORE

Another week of White House chaos and American gun violence. Amid it all, we tried to parse what the Trump administration's 2019 budget...

 
 
 
Celularity Raises $250M to Make Stem Cell Treatments for Cancer & More

CELULARITY RAISES $250M TO MAKE STEM CELL TREATMENTS FOR CANCER & MORE

The placenta provides a fetus all of the nourishment it needs to grow and remain healthy. Executives at biotech startup Celularity...

ICYMI: Insights from my time with Vicki Sato at BIO CEO & Investor Conference

ICYMI: INSIGHTS FROM MY TIME WITH VICKI SATO AT BIO CEO & INVESTOR CONFERENCE

At this week's BIO CEO & Investor Conference the idea of saving the “best for last” certainly did apply. I had the great pleasure of...

 
 
 
Stem Cell Firm Cellular Dynamics to Provide Heart Cells to Takeda

STEM CELL FIRM CELLULAR DYNAMICS TO PROVIDE HEART CELLS TO TAKEDA

Fujifilm said it plans to use stem cells developed by Cellular Dynamics International, a Wisconsin-based company it owns, as part of...

BIOCEO18 “A Moment Decades in the Making”

BIOCEO18 “A MOMENT DECADES IN THE MAKING”

It's a first-of-its-kind gene therapy ever approved by the U.S. Food and Drug Administration, marking yet another critical milestone...

 
 
 

PANCREATIC CANCER DRUG SHOWS MORE SIGNS OF EFFICACY

A cancer drug from San Diego's MabVax Therapeutics Holdings has shown positive early results in treating pancreatic cancer, the company...

SIRENAS ENTERS INTO MULTI-TARGET COLLABORATION WITH BRISTOL-MYERS SQUIBB

Bristol-Myers Squibb to apply Sirenas' proprietary drug discovery technology, ATLANTIS, to multiple challenging therapeutic targets- SAN...

 
 
 

HIGH-DOSE AAV GENE THERAPY APPEARS TOXIC IN MONKEYS AND PIGLETS

Posted on: 6 February 2018, A gene therapy trial that recently led to dramatic benefits for babies born with a fatal neuromuscular...

Shark Tank Update: DreamPad

SHARK TANK UPDATE: DREAMPAD

DreamPad Company : DreamPad Founder : Randall Redfield Season : Appeared on season 9 in the week 6 episode DreamPad is a therapeutic...

 
 
 
Cover Picture: Biotechnology Journal 2/2018

COVER PICTURE: BIOTECHNOLOGY JOURNAL 2/2018

The work developed during the last decades in the research lab to develop genetic engineering tools for the generation and improvement...

A Three-Dimensional Arrayed Microfluidic Blood-Brain Barrier Model With Integrated Electrical Sensor Array

A THREE-DIMENSIONAL ARRAYED MICROFLUIDIC BLOOD-BRAIN BARRIER MODEL WITH INTEGRATED ELECTRICAL SENSOR ARRAY

The blood-brain barrier poses a unique challenge to the development of therapeutics against neurological disorders due to its impermeability...

 
 
 
 
 
 
Activating Sleeping Neurons Reverses Rett Syndrome Symptoms

ACTIVATING SLEEPING NEURONS REVERSES RETT SYNDROME SYMPTOMS

Stimulating neurons in the medial prefrontal cortex may be a therapeutic for Rett syndrome patients.

Potential Therapeutic Target for Diabetes - Sirtuin Enzyme

POTENTIAL THERAPEUTIC TARGET FOR DIABETES - SIRTUIN ENZYME

Sirtuin enzyme may be a key player in regulating hepatic glucokinase and a potential therapeutic target for type 2 diabetes.